Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;26(3):1779-1821.
doi: 10.1007/s11030-021-10257-9. Epub 2021 Jun 27.

Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development

Affiliations
Review

Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development

Chrisna Matthee et al. Mol Divers. 2022 Jun.

Erratum in

Abstract

Adenosine receptors (ARs) are ubiquitously distributed throughout the mammalian body where they are involved in an extensive list of physiological and pathological processes that scientists have only begun to decipher. Resultantly, AR agonists and antagonists have been the focus of multiple drug design and development programmes within the past few decades. Considered to be a privileged scaffold in medicinal chemistry, the chalcone framework has attracted a substantial amount of interest in this regard. Due to the potential liabilities associated with its structure, however, it has become necessary to explore other potentially promising compounds, such as heterocycles, which have successfully been obtained from chalcone precursors in the past. This review aims to summarise the emerging therapeutic importance of adenosine receptors and their ligands, especially in the central nervous system (CNS), while highlighting chalcone and heterocyclic derivatives as promising AR ligand lead compounds.

Keywords: Adenosine receptors; Central nervous system; Chalcone; Heterocycle.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Feigin VL, Vos T, Abajobir AA et al (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16(11):877–897. https://doi.org/10.1016/S1474-4422(17)30299-5 - DOI
    1. Standaert DG, Roberson ED (2011) Treatment of central nervous system degenerative disorders. In: Brunton LL (ed) Goodman & Gilman’s: the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York, pp 609–628
    1. Fredholm BB (2014) Adenosine—a physiological or pathophysiological agent? J Mol Med 92(3):201–206. https://doi.org/10.1007/s00109-013-1101-6 - DOI - PubMed
    1. Yuzlenko O, Kiec-Kononowicz K (2006) Potent adenosine A1 and A2A receptors antagonists: recent developments. Curr Med Chem 13(30):3609–3625. https://doi.org/10.2174/092986706779026093 - DOI - PubMed
    1. Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z (2017) Chalcone: a privileged structure in medicinal chemistry. Chem Rev 117(12):7762–7810. https://doi.org/10.1021/acs.chemrev.7b00020 - DOI - PubMed - PMC

LinkOut - more resources